How to Reduce Man Boobs: Causes and Treatment

How to reduce man boobs is a question many men find difficult to raise, yet it is a common and very treatable concern. Chest enlargement in men can stem from true gynaecomastia, which involves glandular breast tissue growth driven by hormonal imbalance, or from pseudogynaecomastia, which is simply excess fatty tissue over the chest. The right approach depends entirely on which type you have. This article explains the causes, when to see a GP, what NHS treatments are available, and how lifestyle changes, medication and surgery may each play a role in managing the condition.

What causes man boobs and is it gynaecomastia or excess fat?

Man boobs are caused by either true gynaecomastia, involving glandular tissue growth from an oestrogen-androgen imbalance, or pseudogynaecomastia, which is excess chest fat. A GP can distinguish between the two through clinical examination and targeted investigations.

Man boobs are caused either by true gynaecomastia, which is the benign enlargement of glandular breast tissue in males, or by pseudogynaecomastia, which is the accumulation of fatty tissue over the chest without any glandular change. Distinguishing between the two matters because the underlying cause determines which treatments are likely to help. True gynaecomastia results from an imbalance between oestrogen and androgen activity in breast tissue.^[1][2] This can occur at predictable life stages, including newborn infancy, puberty and older age, but it can also be triggered by a range of medicines, recreational drugs, alcohol excess, liver disease, thyroid disorders or tumours affecting hormone-producing glands.

Common medicines associated with gynaecomastia include spironolactone, cimetidine, some antipsychotics, anabolic steroids, finasteride and certain antiretrovirals.^[1] Cannabis and other recreational drugs have also been implicated. This list is illustrative rather than exhaustive; the NHS and NICE CKS guidance on gynaecomastia provide a fuller account of implicated medicines, and you should not stop any prescribed medicine without first speaking to your GP, as abrupt withdrawal can carry its own risks.

Pseudogynaecomastia, by contrast, is directly linked to overall body fat distribution and does not involve glandular proliferation. In practice, some men have a combination of both. A GP can usually distinguish between the two through clinical examination, feeling for a firm or rubbery disc of tissue beneath the nipple that is characteristic of true gynaecomastia. Blood tests and, occasionally, imaging may be arranged to identify any hormonal or systemic cause. Where a testicular cause is suspected, the GP may also examine the testes and arrange a testicular ultrasound. Understanding which type you have is the essential first step before considering any intervention.

When should you see a GP about chest swelling or tenderness?

See a GP promptly if you notice a new, firm, one-sided or growing lump beneath the nipple, or any nipple discharge, as male breast cancer must be excluded. NICE NG12 advises urgent two-week-wait referral for unexplained breast lumps in men.

You should see a GP promptly if you notice a new, firm or painful lump beneath one or both nipples, particularly if it is one-sided, growing, or accompanied by nipple discharge. While gynaecomastia is almost always benign, male breast cancer, though rare, does occur, and any unilateral hard lump warrants clinical assessment without delay.

NICE guidance on suspected cancer (NG12) advises that men with an unexplained breast lump should be referred urgently under the two-week-wait pathway for specialist review.^[3] Additional features that should prompt urgent referral include unilateral nipple changes in men aged 50 or over, an unexplained axillary mass, and persistent or bloody nipple discharge. Unilateral eczematous changes to the nipple or areola, which may indicate Paget's disease of the breast, should also be assessed urgently.^[4][5]

Other reasons to consult your GP include breast tenderness that is interfering with daily life, swelling that has appeared suddenly in adulthood without an obvious cause, or changes that coincide with new symptoms such as unexplained weight loss, fatigue or testicular changes. A new testicular mass alongside gynaecomastia warrants prompt GP assessment, as testicular tumours can produce hormones that cause breast tissue changes. These could point to an underlying hormonal or systemic condition that needs investigation in its own right.

If you experience sudden severe chest pain, difficulty breathing or palpitations alongside chest swelling, call 999 immediately, as these symptoms require emergency assessment unrelated to breast tissue. For non-urgent concerns that you would like advice on before a GP appointment, NHS 111 can help you decide on the appropriate next step. In most cases of gradual, bilateral, soft breast enlargement in a teenager or older man, the situation is not an emergency, but a GP review is still worthwhile to rule out a treatable cause and to discuss management options.

What treatments are available on the NHS for gynaecomastia?

NHS treatment ranges from watchful waiting in adolescents to addressing an underlying hormonal cause or switching a causative medicine. Surgery is available in some areas but is often classified as low clinical priority, requiring documented distress or a clear clinical indication.

NHS treatment for gynaecomastia depends on the underlying cause, the severity of symptoms and how long the condition has been present. For many adolescent boys, pubertal gynaecomastia resolves spontaneously within one to two years, and watchful waiting with reassurance is the standard approach recommended in line with NHS and NICE CKS guidance on gynaecomastia.^[1][13] Where a causative medicine has been identified, switching to an alternative under medical supervision may be sufficient to allow the breast tissue to regress.

If an underlying hormonal condition such as hypogonadism or hyperthyroidism is found, treating that condition directly is the priority. Investigations are directed by the clinician based on the clinical picture and commonly include testosterone, luteinising hormone, follicle-stimulating hormone, oestradiol, prolactin, thyroid function, human chorionic gonadotrophin (hCG), and liver and renal function tests. Referral to an endocrinologist or a breast surgeon may follow depending on findings.

Surgical reduction, either liposuction for fatty tissue or subcutaneous mastectomy for glandular tissue, is available on the NHS in some circumstances, but access varies by Integrated Care Board (ICB). Many ICBs classify surgery for gynaecomastia as a procedure of low clinical priority and will only fund it where there is documented psychological distress, significant physical symptoms, or a clear clinical indication, in line with NHS England Evidence-Based Interventions guidance.^[12] A GP referral to a breast or plastic surgery service is the starting point, and the clinical team will assess whether the criteria for NHS funding are met in your area. Private surgical options are also available for those who do not meet NHS thresholds.

Can diet and exercise really help reduce man boobs?

Diet and exercise can meaningfully reduce chest size when the cause is excess fat, but will not significantly shrink glandular breast tissue in true gynaecomastia. Overall fat loss through a calorie deficit and regular activity is the most effective lifestyle approach.

Diet and exercise can meaningfully reduce chest size when the primary cause is pseudogynaecomastia, that is, excess fatty tissue rather than glandular proliferation. Reducing overall body fat through a sustained calorie deficit, combined with regular physical activity, will lead to fat loss across the body including the chest, though the rate and pattern of fat loss varies between individuals and cannot be targeted to one area alone. There is no evidence that any specific exercise selectively removes chest fat faster than others, but resistance training for the pectoral muscles can improve the overall appearance and definition of the chest as fat reduces.

For true gynaecomastia involving glandular tissue, lifestyle changes alone are unlikely to cause significant regression, because the firm disc of breast tissue beneath the nipple is not composed of fat and does not respond to calorie restriction in the same way. However, reducing alcohol intake and avoiding anabolic steroids or other substances known to disrupt hormone balance is clinically sensible and may prevent further progression.

A word of caution on supplements: products marketed as "testosterone boosters" or "oestrogen blockers" are not regulated as medicines in the UK, lack robust clinical evidence, and some contain ingredients that may themselves disrupt hormone balance or interact with prescribed medicines. These should be avoided unless discussed with a clinician.

A balanced diet that supports a healthy weight, rich in vegetables, lean protein and whole grains while limiting ultra-processed foods and excess alcohol, is consistent with NHS Better Health guidance and supports hormonal health more generally. For men who are living with obesity and are finding it difficult to achieve meaningful weight loss through diet and exercise alone, a GP can discuss whether structured weight management support, including referral to a tier 3 service or assessment for pharmacological options, might be appropriate. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where clinically appropriate options may be considered.

Are there medications or surgery options worth considering?

Specialist-initiated off-label SERMs such as tamoxifen or raloxifene may reduce glandular tissue in recent-onset gynaecomastia, while surgery (liposuction or subcutaneous mastectomy) is considered when the condition persists beyond one year and causes significant distress.

Medications are not routinely prescribed on the NHS for gynaecomastia, but in specific clinical circumstances a specialist may consider off-label use of medicines such as tamoxifen or raloxifene, which are selective oestrogen receptor modulators (SERMs). Evidence from small studies suggests these can reduce glandular breast tissue, and they are generally considered most effective when gynaecomastia is recent in onset, typically within the first six to twelve months. Neither medicine holds a UK marketing authorisation specifically for this indication, and their use should only be initiated and monitored by a specialist such as an endocrinologist or breast surgeon.^[8][9] Key risks associated with tamoxifen include venous thromboembolism and vasomotor symptoms; raloxifene carries a similar thromboembolism risk.^[8][9] The BNF monographs for both medicines provide further detail on contraindications, interactions and monitoring. The MHRA authorises medicines for specific indications, and prescribing outside those indications carries additional clinical and legal considerations that a specialist is best placed to manage.

Surgical options include liposuction, which removes fatty tissue, and subcutaneous mastectomy, which removes glandular tissue, or a combination of both depending on the composition of the enlargement. Surgery is generally considered when gynaecomastia has been present for more than one year, has not responded to treatment of an underlying cause, and is causing significant physical discomfort or psychological distress.^[12][13] Results are generally good, but as with any surgical procedure there are risks including scarring, asymmetry, changes in nipple sensation and the possibility of recurrence if the underlying hormonal cause is not addressed.^[12][14] Patient information from surgical societies such as BAAPS (British Association of Aesthetic Plastic Surgeons) and BAPRAS (British Association of Plastic, Reconstructive and Aesthetic Surgeons) can help you understand realistic outcomes and what to expect from a surgical consultation.

Anyone considering surgery privately should ensure their surgeon is on the GMC register at gmc-uk.org and that the facility is regulated by the Care Quality Commission (CQC) in England, Healthcare Improvement Scotland, Healthcare Inspectorate Wales, or the Regulation and Quality Improvement Authority (RQIA) in Northern Ireland, depending on location. A thorough consultation, including discussion of realistic outcomes and risks, is essential before proceeding. Suspected adverse effects from any medicine used in this context can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Frequently Asked Questions